Corporate ActionJun 2, 2026, 05:36 PM
NRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
AI Summary
NRx Pharmaceuticals, Inc. announced its intention to conduct an underwritten public offering of its common stock. The company also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold in the offering. The net proceeds from this offering are intended for working capital and general corporate purposes to support the company's growth.
Key Highlights
- NRx Pharmaceuticals intends to offer shares of common stock in an underwritten public offering.
- Company expects to grant underwriter a 30-day option for up to an additional 15% of shares.
- BTIG, LLC is acting as the lead bookrunner for the offering.
- Lucid Capital Markets, LLC is acting as joint bookrunning manager.
- Net proceeds will be used for working capital and general corporate purposes to support growth.
- The offering is subject to market and other conditions.
Price Impact
More from NRXP